Organizations Filed Purposes:
THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION (ACCRF) SUPPORTS RESEARCH INTO ADENOID CYSTIC CARCINOMA THAT WILL ACCELERATE THE DEVELOPMENT OF IMPROVED THERAPIES AND A CURE FOR THE DISEASE.
SUPPORTING RESEARCH INTO THE TREATMENT AND CURE OF ADENOID CYSTIC CARCINOMA.
SPECIMENS AND MODELS: ACCRF SUPPORTS AND COORDINATES THE DEVELOPMENT AND DISTRIBUTION OF BIOBANKING, CELL LINE AND ANIMAL MODEL RESOURCES FOR RESEARCHERS. THESE RESOURCES ARE THE BUILDING BLOCKS UPON WHICH ALL BASIC, TRANSLATIONAL AND CLINICAL RESEARCH ARE CONSTRUCTED.
BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY THE MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE MECHANISMS OF ACTION, RESEARCHERS MAY DISCOVER MORE QUICKLY THE ACHILLES' HEELS OF THE DISEASE.
TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL BENEFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT, PRECLINICAL DRUG SCREENING AND CORRELATIVE STUDIES ARE CRUCIAL TO THE INITIATION AND OPTIMAL CONDUCT OF CLINICAL TRIALS.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Jeffrey A Kaufman | EXECUTIVE DIRECTOR/BOARD CHAIR | 50 | $150,000 |
| Douglas Meyer | DIRECTOR | 5 | $0 |
| Marnie A Kaufman | CFO | 25 | $0 |
| Lisa Bakri | DIRECTOR | 5 | $0 |
| Ralph Mollis | TREASURER | 5 | $0 |
| Thomas Dilenge | BOARD VICE CHAIR | 5 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202121349349302482_public.xml